Condition (MeSH)
Hyper-IgM Immunodeficiency Syndrome
ClinicalTrials.gov lists 22 trials for Hyper-IgM Immunodeficiency Syndrome or a narrower condition beneath it. National Human Genome Research Institute (NHGRI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 22 trials are tagged with Hyper-IgM Immunodeficiency Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Hyper-IgM Immunodeficiency Syndrome trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2017 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 2 |
| 2012 | 2 |
| 2011 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyper-IgM Immunodeficiency Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 3 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 8 |
How many Hyper-IgM Immunodeficiency Syndrome trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 11 |
| Terminated | 2 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyper-IgM Immunodeficiency Syndrome trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 2 |
| Celldex Therapeutics | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| FFF Enterprises | 1 |
| Instituto Grifols, S.A. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Hyper-IgM Immunodeficiency Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 2 |
| Busulfan | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Globulin, Immune | 3 |
| Hematopoietic Stem Cell Transplant | 2 |
| AG chemotherapy | 1 |
| Flebogamma 5% DIF | 1 |
| data collection | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hyper-IgM Immunodeficiency Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac arrest | 2 | 1 |
| Respiratory failure | 2 | 1 |
| Sepsis | 2 | 1 |
| left lower lobe pneumonia | 2 | 1 |
| Acute Gastroenterirtis (AGE) | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hyper-IgM Immunodeficiency Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. | EMBO molecular medicine | 2021 | Yes |
| Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. | The Journal of allergy and clinical immunology | 2017 | Yes |
| Ataxia-telangiectasia: Immunodeficiency and survival. | Clinical immunology (Orlando, Fla.) | 2017 | Yes |
| Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. | Clinical and experimental immunology | 2010 | Yes |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hyper-IgM syndrome without susceptibility to opportunistic infections | 183666 | Exact | Orphadata Science knowledge files, Product 1 |
| Hyper-IgM syndrome without susceptibility to opportunistic infections | 183666 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.